当前位置: X-MOL 学术J. Cell. Mol. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma
Journal of Cellular and Molecular Medicine ( IF 4.3 ) Pub Date : 2021-09-12 , DOI: 10.1111/jcmm.16928
Jeff Yat-Fai Chung 1 , Max Kam-Kwan Chan 1 , Philip Chiu-Tsun Tang 1 , Alex Siu-Wing Chan 2 , Justin Shing-Yin Chung 1 , Xiao-Ming Meng 3 , Ka-Fai To 1 , Hui-Yao Lan 4 , Kam-Tong Leung 5 , Patrick Ming-Kuen Tang 1
Affiliation  

Cancer cells are high in heterogeneity and versatility, which can easily adapt to the external stresses via both primary and secondary resistance. Targeting of tumour microenvironment (TME) is a new approach and an ideal therapeutic strategy especially for the multidrug resistant cancer. Recently, we invented AANG, a natural compound formula containing traditional Chinese medicine (TCM) derived Smad3 inhibitor Naringenin (NG) and Smad7 activator Asiatic Acid (AA), for rebalancing TGF-β/Smad signalling in the TME, and its implication on the multidrug resistance is still unexplored. Here, we observed that an equilibrium shift of the Smad signalling in patients with hepatocellular carcinoma (HCC), which was dramatically enhanced in the recurrent cases showing p-glycoprotein overexpression. We optimized the formula ratio and dosage of AANG that effectively inhibit the proliferation of our unique human multidrug resistant subclone R-HepG2. Mechanistically, we found that AANG not only inhibits Smad3 at post-transcriptional level, but also upregulates Smad7 at transcriptional level in a synergistic manner in vitro. More importantly, AANG markedly suppressed the growth and p-glycoprotein expression of R-HepG2 xenografts in vivo. Thus, AANG may represent a novel and safe TCM-derived natural compound formula for overcoming HCC with p-glycoprotein-mediated multidrug resistance.

中文翻译:

AANG:一种通过协同重新平衡肝细胞癌中的 TGF-β/Smad 信号来克服多药耐药性的天然化合物配方

癌细胞具有高度的异质性和多功能性,可以通过初级和次级阻力轻松适应外部压力。靶向肿瘤微环境(TME)是一种新的治疗方法,也是一种理想的治疗策略,尤其是针对耐多药癌症。最近,我们发明了 AANG,这是一种含有中药 (TCM) 衍生的 Smad3 抑制剂柚皮素 (NG) 和 Smad7 激活剂积雪草酸 (AA) 的天然复合配方,用于重新平衡 TME 中的 TGF-β/Smad 信号,及其对多药耐药性仍未探索。在这里,我们观察到 Smad 信号在肝细胞癌 (HCC) 患者中的平衡转移,这在显示 p-糖蛋白过表达的复发病例中显着增强。我们优化了 AANG 的配方比例和剂量,有效抑制了我们独特的人类多药耐药亚克隆 R-HepG2 的增殖。在机制上,我们发现 AANG 不仅在转录后水平抑制 Smad3,而且在体外以协同方式上调转录水平的 Smad7。更重要的是,AANG 在体内显着抑制了 R-HepG2 异种移植物的生长和 p-糖蛋白表达。因此,AANG 可能代表一种新颖且安全的中药衍生天然化合物配方,用于克服 p-糖蛋白介导的多药耐药性 HCC。更重要的是,AANG 在体内显着抑制了 R-HepG2 异种移植物的生长和 p-糖蛋白表达。因此,AANG 可能代表一种新颖且安全的中药衍生天然化合物配方,用于克服 p-糖蛋白介导的多药耐药性 HCC。更重要的是,AANG 在体内显着抑制了 R-HepG2 异种移植物的生长和 p-糖蛋白表达。因此,AANG 可能代表一种新颖且安全的中药衍生天然化合物配方,用于克服 p-糖蛋白介导的多药耐药性 HCC。
更新日期:2021-10-12
down
wechat
bug